SCHEMBL1168026

SCHEMBL1168026

CC(=O)c1ccc(Cn2ccc(NC(=O)c3nc(C)oc3-c3ccc(Cl)cc3)n2)o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
LMNA P02545 6/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
TP53 P04637 1/20 0.45
ALDH1A1 P00352 5/20 0.45
TSHR P16473 4/20 0.45
HPGD P15428 4/20 0.45
NPSR1 Q6W5P4 4/20 0.45
HSD17B10 Q99714 3/20 0.45
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
FPR2 P25090 1/20 0.43
CACNA1G O43497 2/20 0.42
CACNA1H O95180 2/20 0.42
CACNA1I Q9P0X4 2/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1166301 0.92 FPR2 (0.51) SMN1; SMN2MEN1KMT2ALMNANPC1
SCHEMBL1166848 0.91 SMN1; SMN2 (0.56) SMN1; SMN2MEN1KMT2ALMNANPC1
SCHEMBL1166207 0.90 TP53 (0.45) SMN1; SMN2MEN1KMT2ALMNANPC1
SCHEMBL1167319 0.89 HCRTR1 (0.46) SMN1; SMN2MEN1KMT2ALMNANPC1
SCHEMBL1165767 0.87 HCRTR1 (0.55) SMN1; SMN2MEN1KMT2ALMNANPC1
SCHEMBL1166216 0.86 HCRTR1 (0.47) SMN1; SMN2MEN1KMT2ALMNANPC1
SCHEMBL1165978 0.85 FPR2 (0.57) SMN1; SMN2MEN1KMT2ALMNANPC1
SCHEMBL1167135 0.85 FPR2 (0.51) SMN1; SMN2MEN1KMT2ANPC1RAB9A
SCHEMBL1166817 0.85 ALDH1A1 (0.46) SMN1; SMN2MEN1KMT2ALMNANPC1
SCHEMBL1166778 0.84 TP53 (0.56) SMN1; SMN2MEN1KMT2ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES CYP3A43, CYP1A2, CYP3A5 SMN1; SMN2 4612/4885MEN1 2602/4885KMT2A 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.